Press release 19.03.2026
For as long as she can remember, Line Debois wanted to build something that could help patients. Growing up with a mother living with a serious lung disease, she was drawn early to the idea of developing treatments and technologies that could make a real difference. That motivation eventually led her into research and, later, to MedicQuant, where she and Co-founder Malthe are now building a diagnostic tool designed to help doctors make faster decisions in one of healthcare’s most time critical situations.
Today, MedicQuant announces the initial close of its DKK 22 million seed round lead by Delphinus Venture Capital and new participation from several business angels, alongside full follow‑on investment from all existing investors, including the Export and Investment Fund of Denmark (EIFO).
The Aarhus based medtech company is developing a rapid point of care test platform to detect the levels of anticoagulants also known as blood thinners in patients with suspected stroke, helping clinicians determine faster whether a patient can safely receive treatment. The detection of anticoagulants marks only the initial use of the platform, with significant potential to address a wide range of unmet clinical challenges.
One of the most urgent needs in healthcare
Stroke is a major and growing health challenge. Around 12,000 people in Denmark are affected every year and globally stroke causes more than 6.5 million deaths annually (World Stroke Organization). For patients, families, and healthcare systems alike, the consequences can be profound.
In stroke care, clinicians often use the phrase “time is brain” because every minute matters. Fast treatment can be decisive for survival and for reducing the risk of lasting injury. Yet when a patient arrives at the hospital on newer anticoagulants, doctors often need fast answers before they can move forward with treatment. In many settings, those answers are not readily available at the bedside. That can delay critical decisions in a part of the healthcare system where time, capacity, and certainty are already under pressure.
“The first time a stroke patient gets faster treatment because our device helped doctors reach an answer sooner, that will mean everything,” says Line, CEO & Co-founder of MedicQuant. “That is the future we are working toward.”
A clear clinical need in stroke care
MedicQuant’s focus on stroke care is rooted in a challenge clinicians know well.
“This is a real clinical problem that doctors are facing, and we have a technology that can address this huge unmet need,” says Malthe, CTO & Co-founder and of MedicQuant. “The more physicians we spoke to, the clearer it became that faster answers will make a meaningful difference, both for patients and for the teams making decisions under intense time pressure.”
By helping clinicians reach answers faster, MedicQuant aims to support not only better and more confident treatment decisions, but also a more efficient acute care pathway in a healthcare system where every minute and every resource matter.
Advancing the next phase of MedicQuant
With the seed investment, MedicQuant will finish the product development, expanding analytical verification and pre-commercial activities, and preparing for the clinical studies.
For Delphinus Venture Capital, the company stands out for both the strength of its team and the clarity of its mission.
“MedicQuant is tackling a serious and time sensitive challenge in healthcare with a solution grounded in real clinical need,” says Katrine Haahr Riisberg, Investment Associate at Delphinus Venture Capital. “What impressed us was not only the scientific foundation, but also the way Line, Malthe and the team have worked closely with clinicians to understand where they can create the greatest impact.”
About MedicQuant
MedicQuant is a spin-out from the Gothelf Lab at iNANO, Aarhus University, Denmark, and stands on the foundation of more than 11 years of state-of-the-art research. MedicQuant has developed a proprietary point‑of‑care DNA nanotechnology platform that measures small molecules with laboratory‑level accuracy in 10 minutes designed to address major clinical challenges.
About Delphinus Venture Capital
Delphinus Venture Capital is a Danish venture fund established in 2025, managing DKK 600 million. The fund is backed by Aarhus University Research Foundation, HEARTLAND, Norlys, and Salling Group, and invests in research-driven innovation and deep tech companies with the potential to create global impact.
For further information:
Line Debois, PhD, CEO & Co-Founder, MedicQuant
Tlf.: +45 31 22 84 10
Email: ldn@medicquant.com
Katrine Riisberg, Investment Associate, Delphinus Venture Capital
Tlf.: + 45 28 83 28 78
Email: khr@delphinus.vc